Atypical femoral fractures during prolonged use of bisphosphonates: Short-term responses to strontium ranelate and teriparatide

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 9, 2011, Pages 2675-2680

  Carvalho, Nara Nóbrega Crispim ^a   Voss, L A ^a   Almeida, M O P ^a   Salgado, C L ^a   Bandeira, F ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CALCIUM CARBONATE; CARBOXY TERMINAL TELOPEPTIDE; COLECALCIFEROL; IBANDRONIC ACID; OSTEOCALCIN; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; STRONTIUM RANELATE; ZOLEDRONIC ACID;

ADULT; AGED; ATYPICAL FEMORAL FRACTURE; BONE DENSITY; CASE REPORT; CONFERENCE PAPER; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FALLING; FEMALE; FEMUR FRACTURE; FEMUR NECK; FEMUR SUBTROCHANTERIC FRACTURE; FRACTURE HEALING; FRACTURE NONUNION; HUMAN; LUMBAR SPINE; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; TIBIA FRACTURE;

AGED; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; FEMORAL FRACTURES; HUMANS; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS; TERIPARATIDE; THIOPHENES;

EID: 80052540017     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-0593     Document Type: Conference Paper

References (28)

1. Lenart B.A., Lorich D.G., Lane J.M. 2008 Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358:1304-1306 (Pubitemid 351439247)
2. Geusens P. 2009 Strategies for treatment to prevent fragility fractures in postmenopausal women. Best Pract Res Clin Rheumatol 23:727-740
3. Black D.M., Kelly M.P., Genant H.K., Palermo L., Eastell R, Bucci- Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, de Papp A, Bauer DC 2010 Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 362:1761-1771
4. Lenart B.A., Neviaser A.S., Lyman S., Chang C.C., Edobor-Osula F., Steele B., Van der Meulen M.C.,Lorich D.G., Lane J.M. 2009 Association of low-energy femoral fractures with prolonged bisphosphonate use: A case control study. Osteoporos Int 20:1353-1362
5. Odvina C.V., Zerwekh J.E., Rao D.S., Maalouf N., Gottschalk F.A., Pak C.Y. 2005 Severely suppressed bone turnover: A potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294-1301 (Pubitemid 40463979)
6. Cortet B. 2009 Strontium ranelate: New perspectives for the management of osteoporosis. Reumatology (Oxford) 48 (Suppl 4):iv1-iv2
7. Shane E., Burr D., Ebeling P.R., Abrahamsen B., Adler R.A., Brown T.D., CheungAM,CosmanF, Curtis JR, Dell R, Dempster D, EinhornTA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M 2010 Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267-2294
8. Odvina C.V., Levy S., Rao S., Zerwekh J.E., Rao D.S. 2010 Unusual mid-shaft fractures during long term bisphosphonate therapy. Clin Endocrinol (Oxf) 72:161-168
9. Abrahamsen B., Eiken P., Eastell R. 2009 Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: A registerbased national cohort study. J Bone Miner Res 24:1095-1102
10. Kwek E.B., Goh S.K., Koh J.S., Png M.A., Howe T.S. 2008 An emerging pattern of subtrochanteric stress fractures: A long-term complication of alendronate therapy? Injury 39:224-231
11. Grant A.M., Avenell A., Campbell M.K., McDonald A.M., MacLennan G.S., McPherson G.C., Anderson F.H., Cooper C., Francis R.M., Donaldson C., Gillespie W.J., Robinson C.M., Torgerson D.J., Wallace W.A. 2005 Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): A randomized placebo-controlled trial. Lancet 365:1621-1628 (Pubitemid 40693411)
12. Tarantino U., Celi M., Saturnino L., Scialdoni A., Cerocchi I. 2010 Strontium ranelate and bone healing: Report of two cases. Clin Cases Miner Bone Metab 7:65-68
13. Salvin S., Quartuccio L., Maset M., Lombardi S., Sacco S., Mansutti E., De Vita S. 2009 Strontium ranelate and femural fracture healing during rheumatoid arthritis and osteoporosis. Bone 45:S14 (Abstract)
14. Ozturan K.E., Demir B., Yucel I., Çakici H., Yucel F., Haberal A. 2009 Effect of strontium ranelate on fracture healing in the osteoporotic rat model. Fertil Steril 92:S1 (Abstract)
15. Cebesoy O., Tutar E., Kose K.C., Baltaci Y., Bagci C. 2007 Effect of strontium ranelate on fracture healing in rat tibia. Joint Bone Spine 74:590-593 (Pubitemid 350236018)
16. Li Y.F., Luo E., Feng G., Zhu S.S., Li J.H., Hu J. 2010 Systemic treatment with strontium ranelate promotes tibial fracture healing in ovariectomized rats. Osteoporos Int 21:1889-1897
17. Bruyère O., Collette J., Rizzoli R., Decock C., Ortolani S., Cormier C., Detilleux J., Reginster J.Y. 2010 Relationship between 3-month changes in biochemical markers of bone remodeling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years. Osteoporos Int 21:1031-1036
18. Meunier P.J., Roux C., Ortolani S., Diaz-Curiel M., Compston J., Marquis P., Cormier C., Isaia G., Badurski J., Wark J.D., Collette J., Reginster J.Y. 2009 Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausalwomenwith osteoporosis. Osteoporos Int 20:1663-1673
19. Meunier P.J., Roux C., Seeman E., Ortolani S., Badurski J.E., Spector T.D., Cannata J., Balogh A., Lemmel E.M., Pors-Nielsen S., Rizzoli R., Genant H.K., Reginster J.Y. 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459-468 (Pubitemid 38133766)
20. Reginster J.Y., Seeman E., De Vernejoul M.C., Adami S., Compston J., Phenekos C., Devogelaer J.P., Curiel M.D., Sawicki A., Goemaere S., Sorensen O.H., Felsenberg D., Meunier P.J. 2005 Strontium ranelate reduces risk of nonvertebral fracture in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816-2822 (Pubitemid 40686329)
21. Reginster J.Y., Felsenberg D., Boonen S., Diez-Perez A., Rizzoli R., Brandi M.L., Spector T.D., Brixen K., Goemaere S., Cormier C., BaloghA., Delmas P.D., Meunier P.J. 2008 Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fracture in postmenopausal osteoporosis. Arthritis Rheum 58:1687-1695 (Pubitemid 351847521)
22. Seeman E., Boonen S., Borgström F., Vellas B., Aquino J.P., Semler J., Benhamou C.L., Kaufman J.M., Reginster J.Y. 2010 Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining lifeyears in women over 80 years of age. Bone 46:1038-1042
23. Kendler D.L. 2006 Strontium ranelate-data on vertebral and nonvertebral fracture efficacy and safety: Mechanism of action. Curr Osteoporos Rep 4:34-39 (Pubitemid 44623946)
24. Aspenberg P., Genant H.K., Johansson T., Nino A.J., See K., Krohn K., García-Hernaaposndez P.A., Recknor C.P., Einhorn T.A., Dalsky G.P., Mitlak B.H., Fierlinger A., Lakshmanan M.C. 2010 Teriparatide for acceleration of fracture repair in humans: A prospective, randomized,double-blind study of 102 postmenopausalwomenwith distal radial fractures. J Bone Miner Res 25:404-414
25. Canalis E., Giustina A., Bilezikian J.P. 2007 Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 357:905-916
26. Borba V.Z., Mañas N.C. 2010 The use of PTH in the treatment of osteoporosis. Arq Bras Endocrinol Metabol 54:213-219
27. Habermann B., Kafchitsas K., Olender G., Augat P., Kurth A. 2010 Strontium ranelate enhances callus strength more than PTH 1-34 in an osteoporotic rat model of fracture healing. Calcif Tissue Int 86: 82-89
28. Sousa I.O., Diniz E.T., Marques T.F., Griz L., Coutinho Mde A., Bandeira F. 2010 Short-term bone marker responses to teriparatide and strontium ranelate in patients with osteoporosis previously treated with bisphosphonates. Arq Bras Endocrinol Metabol 54:244-249